Morris Nicolette T, Taylor Mihaela B, Hacobian Melkon, Olevsky Olga M, Kermani Tanaz A
Division of Rheumatology, University of California, Los Angeles, David Geffen School of Medicine, California, USA.
University of California, Los Angeles, David Geffen School of Medicine, California, USA.
Leuk Res Rep. 2020 Jun 18;14:100214. doi: 10.1016/j.lrr.2020.100214. eCollection 2020.
An association between tyrosine-kinase inhibitor therapy for chronic myeloid leukemia and vascular adverse events including peripheral arterial disease, coronary artery disease, and pulmonary hypertension has been described. We present a patient who developed isolated pulmonary artery vasculitis resulting in left pulmonary artery stenosis, in addition to left coronary artery stenosis while on nilotinib. While monitoring for cardiovascular events is important, clinicians should also recognize possible drug-induced vasculitis during chronic nilotinib therapy.
酪氨酸激酶抑制剂治疗慢性髓性白血病与包括外周动脉疾病、冠状动脉疾病和肺动脉高压在内的血管不良事件之间的关联已被描述。我们报告了一名患者，在使用尼罗替尼治疗期间，除了左冠状动脉狭窄外，还发生了孤立性肺动脉血管炎，导致左肺动脉狭窄。虽然监测心血管事件很重要，但临床医生也应认识到慢性尼罗替尼治疗期间可能出现的药物性血管炎。
